Journal September 26, 2026 7 min read

Common Misconceptions About Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) is a method for tracking interstitial glucose, not a diagnostic or therapeutic tool. This article examines common misconceptions and the research studies that address them.

peptides-pro Editorial

What Continuous Glucose Monitoring Actually Is

Continuous glucose monitoring (CGM) is a method for measuring glucose concentrations in interstitial fluid, typically via a subcutaneous sensor that transmits data to a receiver or smartphone. Unlike self-monitoring of blood glucose (SMBG), which provides discrete capillary blood glucose readings from fingerstick samples, CGM systems generate frequent or near-continuous glucose values and can calculate metrics such as time in range. CGM is not a therapeutic intervention; it is a monitoring technology used in research and clinical care to characterize glycemic patterns.

The research studies described below centre on glucose homeostasis and its measurement across different populations, including individuals with type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), pregestational diabetes, and other metabolic conditions.

Research Studies

Continuous glucose monitoring and glycemic homeostasis in T2DM with chronic renal insufficiency

A prospective, randomized, active-controlled, multicenter clinical study is planned to evaluate whether dorzagliatin improves glycemic homeostasis in patients with T2DM complicated by chronic renal insufficiency, compared with linagliptin [1]. The study plans to enroll 206 eligible patients with moderate to severe chronic renal insufficiency (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m²). After screening, participants enter a 2-week run-in period consisting of diet and exercise control together with continuous glucose monitoring [1]. This study uses CGM as a tool to assess glycemic control in a population with impaired kidney function, a group in which glucose monitoring can be particularly challenging.

Continuous glucose monitoring versus self-monitoring of blood glucose in women with gestational diabetes

Gestational diabetes mellitus (GDM) is first diagnosed during pregnancy and is associated with increased risks for both mother and baby, including macrosomia, need for insulin treatment, and high blood pressure during pregnancy [2]. The usual method for monitoring blood glucose in women with GDM is self-monitoring of blood glucose (SMBG), which involves finger pricking several times a day [2]. A clinical study is comparing CGM with SMBG in this population [2]. This addresses the misconception that CGM is only for type 1 diabetes; research is exploring its use in gestational diabetes as well.

Continuous glucose monitoring in pregestational diabetes management with insulin glargine

A study is investigating whether taking insulin glargine twice a day instead of once a day better manages pregestational diabetes in pregnant patients [4]. Participants are randomly assigned to once-daily or twice-daily insulin glargine, and continuous glucose monitoring is used to track blood sugar levels [4]. The main question is whether twice-daily dosing leads to better glucose time in range [4]. This study illustrates that CGM is used as an outcome measurement tool in trials evaluating insulin regimens, not as a standalone therapy.

Continuous glucose monitoring and person-reported outcomes with the Accu-Chek SmartGuide system

A controlled pre-post trial is testing the Accu-Chek SmartGuide continuous glucose monitoring system and whether its predictive features provide additional benefits for adults with type 1 diabetes or insulin-treated type 2 diabetes [7]. The study aims to answer whether using the SmartGuide together with the Predict App changes participants' fear of hypoglycemia, and whether the Predict App affects psychological and behavioral outcomes such as sleep quality, confidence in preventing hypoglycemia, diabetes-related distress, and diabetes empowerment [7]. It also examines whether the predictive features affect glucose levels and how participants use the system [7]. This study addresses the misconception that CGM only provides glucose numbers; it may also influence psychological and behavioral factors.

Continuous glucose monitoring in chronic pancreatitis research

The Biobank Integrating Longitudinal ERCP within a Prospective Chronic Pancreatitis Cohort (BILE-CP) is a prospective longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China [3]. The study plans to consecutively enroll 1,500 patients with chronic pancreatitis for long-term follow-up every 6 months, with a particular focus on a sub-cohort undergoing ERCP treatments [3]. During baseline and follow-up visits, researchers will collect multidimensional data, including sociodemographics, diet and lifestyle, emotional status, and sleep [3]. While the provided evidence does not specify CGM use in this cohort, the study's comprehensive data collection may include glycemic monitoring as part of its multidimensional approach. This highlights that CGM can be integrated into broader research contexts beyond diabetes.

Continuous glucose monitoring in exercise response research

An observational study aims to evaluate multilevel physiological, molecular, metabolic, intestinal, immunological, and psychophysiological responses to rowing-specific exercise in elite rowers [5]. Thirty members of the Polish Youth National Rowing Team, aged 19-24 years, will participate during two different training periods [5]. During the competitive phase, participants perform a 2000-m maximal rowing test [5]. The study investigates how maximal and prolonged rowing ergometer exercise influences integrated adaptive mechanisms related to mitochondrial function, metabolic regulation, intestinal permeability, immune activation, DNA damage response, and psychological status [5]. Although the evidence does not explicitly mention CGM, metabolic regulation is a focus, and CGM could be a tool for tracking glucose during exercise in such research. This addresses the misconception that CGM is only for diabetes management; it can be used in exercise physiology studies.

Continuous glucose monitoring in metformin withdrawal research

A clinical trial is investigating how a short-term interruption of metformin treatment affects insulin sensitivity, glucose control, and metabolic flexibility in adults with metabolic syndrome who are taking metformin as part of their usual medical treatment [6]. The study aims to understand whether stopping metformin for 14 days leads to rapid changes in glucose metabolism or whether the effects of previous metformin treatment may persist during a short period without the medication [6]. CGM may be used to assess glucose control in this context, though the provided evidence does not specify its use. This study addresses the misconception that CGM is only for insulin-treated diabetes; it can be relevant in research on non-insulin therapies.

Continuous glucose monitoring in weight maintenance research

A multi-center 2-arm randomized controlled trial across six regions in China is targeting overweight or obese adults who have recently achieved a short-term weight reduction (≥5% of body weight) [8]. The trial will evaluate whether a 10-hour daily Time-Restricted Eating (TRE) regimen can more effectively prevent weight regain compared to standard weight maintenance counseling alone [8]. Both groups receive the same frequency and intensity of nutritional counseling for weight maintenance [8]. While CGM is not mentioned in the provided evidence for this study, it could be used to monitor glycemic variability in weight management research. This addresses the misconception that CGM is only for diabetes; it may also be relevant in obesity and weight maintenance studies.

Continuous glucose monitoring in other metabolic and endocrine contexts

Reference-only evidence includes studies on macronutrient boluses in the context of a low-carbohydrate diet [9], pituitary tumour shrinkage and diabetic remission in cats with Cushing syndrome treated with cabergoline [10], and hypoglycemia associated with median arcuate ligament syndrome surgery [11]. These studies report findings related to glucose metabolism and monitoring in various models and populations. Additionally, a hypothesis-generating narrative review discusses continuous glucose monitoring as a candidate precision tool for cardiovascular prevention and healthy longevity [12]. These references support the broader context of CGM research but are not the focus of this article.

If you are reading this for personal health reasons

The materials and information discussed here are sold for laboratory research purposes only. We do not provide dosing, medical guidance, or personal health advice. Anyone considering the use of any compound or device for themselves should consult a licensed clinician.